Cover Image

Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study

Objectives To assess the risk of flare and damage accrual after tapering glucocorticoids (GCs) in modified serologically active clinically quiescent (mSACQ) patients with systemic lupus erythematosus (SLE). Methods Data from a 12-country longitudinal SLE cohort, collected prospectively between 2013...

Full description

Saved in:
Bibliographic Details
Main Authors: Katsumata, Yasuhiro, Inoue, Eisuke, Harigai, Masayoshi, Cho, Jiacai, Louthrenoo, Worawit, Hoi, Alberta, Golder, Vera, Lau, Chak Sing, Lateef, Aisha, Chen, Yi-Hsing, Luo, Shue-Fen, Wu, Yeong-Jian Jan, Hamijoyo, Laniyati, Li, Zhanguo, Sockalingam, Sargunan, Navarra, Sandra, Zamora, Leonid, Hao, Yanjie, Zhang, Zhuoli, Chan, Madelynn, Oon, Shereen, Ng, Kristine, Kikuchi, Jun, Takeuchi, Tsutomu, Goldblatt, Fiona, O'Neill, Sean, Tugnet, Nicola, Law, Annie Hui Nee, Bae, Sang-Cheol, Tanaka, Yoshiya, Ohkubo, Naoaki, Kumar, Sunil, Kandane-Rathnayake, Rangi, Nikpour, Mandana, Morand, Eric F.
Format: Article
Published: BMJ Publishing Group 2024
Subjects:
R Medicine (General)
Online Access:http://eprints.um.edu.my/47039/
https://doi.org/10.1136/ard-2023-225369
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives To assess the risk of flare and damage accrual after tapering glucocorticoids (GCs) in modified serologically active clinically quiescent (mSACQ) patients with systemic lupus erythematosus (SLE). Methods Data from a 12-country longitudinal SLE cohort, collected prospectively between 2013 and 2020, were analysed. SLE patients with mSACQ defined as the state with serological activity (increased anti-dsDNA and/or hypocomplementemia) but without clinical activity, treated with <= 7.5 mg/day of prednisolone-equivalent GCs and not-considering duration, were studied. The risk of subsequent flare or damage accrual per 1 mg decrease of prednisolone was assessed using Cox proportional hazard models while adjusting for confounders. Observation periods were 2 years and censored if each event occurred. Results Data from 1850 mSACQ patients were analysed: 742, 271 and 180 patients experienced overall flare, severe flare and damage accrual, respectively. Tapering GCs by 1 mg/day of prednisolone was not associated with increased risk of overall or severe flare: adjusted HRs 1.02 (95% CI, 0.99 to 1.05) and 0.98 (95% CI, 0.96 to 1.004), respectively. Antimalarial use was associated with decreased flare risk. Tapering GCs was associated with decreased risk of damage accrual (adjusted HR 0.96, 95% CI, 0.93 to 0.99) in the patients whose initial prednisolone dosages were >5 mg/day. Conclusions In mSACQ patients, tapering GCs was not associated with increased flare risk. Antimalarial use was associated with decreased flare risk. Tapering GCs protected mSACQ patients treated with >5 mg/day of prednisolone against damage accrual. These findings suggest that cautious GC tapering is feasible and can reduce GC use in mSACQ patients.

Similar Items